Descrizione

Biobanking refers to the process by which samples of bodily fluid or tissue are collected for research use to improve our understanding of health and diseases. The global biobanking market is poised to grow by US$ 18.0 miliardi da 2022 A 2028, registrando un CAGR di 4.5% durante il periodo di previsione, secondo StrategyHelix.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for biobanking. The global biobanking market is segmented on the basis of sample type, tipo, biobank format, ownership, applicazione, e regione. By sample type, the global biobanking market has been segmented into biofluids, DNA/RNA, stem cells, tessuti, altri. The biofluids segment was the largest contributor to the global biobanking market in 2021. Based upon type, the global biobanking market is categorized into partnership, standalone. Secondo la ricerca, the standalone segment had the largest share in the global biobanking market. On the basis of biobank format, the global biobanking market has been segmented into diseased-oriented biobanks, population-based biobanks. The diseased-oriented biobanks segment held the largest revenue share in 2021. By ownership, the global biobanking market has been segmented into national & regional agencies, università, non-profit organization, private organization. Globally, the national & regional agencies segment made up the largest share of the biobanking market. Based on application, the global biobanking market is categorized into research, therapeutics. In termini di geografia, the global biobanking market has been segmented into Asia Pacific, Europa, Nord America, Rest of the World (RoW).

The global biobanking market is highly competitive. As of 2021, the major players in the global biobanking market were All of Us, Auria Biobank, Biobank Graz, BioBank Japan (BBJ), Biobank VAST, China Kadoorie Biobank (CKB), China National GeneBank DataBase (CNGB), Danish National Biobank, deCODE genetics Inc., EuroBioBank, Kaiser Permanente Research Bank, National Liver Disease Biobank, NIGMS Human Genetic Cell Repository, The Cancer Human Biobank (caHUB), THL Biobank/Finnish Institute for Health and Welfare (THL), UK Biobank Limited, Uppsala Biobank. Competitive landscape gives a description of the competitive nature of the global biobanking market and a description of the leading companies. Vengono individuati i principali accordi finanziari che hanno plasmato il mercato negli ultimi anni.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the biobanking market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Sample type: biofluids, DNA/RNA, stem cells, tessuti, altri
Tipo: partnership, standalone
Biobank format: diseased-oriented biobanks, population-based biobanks
Ownership: national & regional agencies, università, non-profit organization, private organization
Applicazione: research, therapeutics
Regione: Asia Pacifico, Europa, Nord America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028
Azienda menzionata: All of Us, Auria Biobank, Biobank Graz, BioBank Japan (BBJ), Biobank VAST, China Kadoorie Biobank (CKB), China National GeneBank DataBase (CNGB), Danish National Biobank, deCODE genetics Inc., EuroBioBank, Kaiser Permanente Research Bank, National Liver Disease Biobank, NIGMS Human Genetic Cell Repository, The Cancer Human Biobank (caHUB), THL Biobank/Finnish Institute for Health and Welfare (THL), UK Biobank Limited, Uppsala Biobank

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global biobanking market
– Identificare le strategie regionali e le priorità strategiche sulla base dei dati locali
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Biobanking market overview
Parte 3. Market breakdown by sample type
– Biofluids
– DNA/RNA
– Stem cells
– Tissues
– Altri
Parte 4. Market breakdown by type
– Partnership
– Standalone
Parte 5. Market breakdown by biobank format
– Diseased-oriented biobanks
– Population-based biobanks
Parte 6. Market breakdown by ownership
– National & regional agencies
– Universities
– Non-profit organization
– Private organization
Parte 7. Market breakdown by application
– Research
– Therapeutics
Parte 8. Market breakdown by region
– Asia Pacifico
– Europa
– Nord America
– Rest of the World (RoW)
Parte 9. Aziende chiave
– All of Us
– Auria Biobank
– Biobank Graz
– BioBank Japan (BBJ)
– Biobank VAST
– China Kadoorie Biobank (CKB)
– China National GeneBank DataBase (CNGB)
– Danish National Biobank
– deCODE genetics, Inc.
– EuroBioBank
– Kaiser Permanente Research Bank
– National Liver Disease Biobank
– NIGMS Human Genetic Cell Repository
– The Cancer Human Biobank (caHUB)
– THL Biobank/Finnish Institute for Health and Welfare (THL)
– UK Biobank Limited
– Uppsala Biobank
Informazioni su StrategyHelix
Disclaimer